357 related articles for article (PubMed ID: 25404585)
1. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
Loomba R; Quehenberger O; Armando A; Dennis EA
J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
[TBL] [Abstract][Full Text] [Related]
2. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
3. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
4. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
[TBL] [Abstract][Full Text] [Related]
5. The plasma lipidomic signature of nonalcoholic steatohepatitis.
Puri P; Wiest MM; Cheung O; Mirshahi F; Sargeant C; Min HK; Contos MJ; Sterling RK; Fuchs M; Zhou H; Watkins SM; Sanyal AJ
Hepatology; 2009 Dec; 50(6):1827-38. PubMed ID: 19937697
[TBL] [Abstract][Full Text] [Related]
6. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.
Alsaqal S; Hockings P; Ahlström H; Gummesson A; Hedström A; Hulthe J; Johansson L; Niessen HG; Schoelch C; Schultheis C; Vessby J; Wanders A; Rorsman F; Ebeling Barbier C
J Magn Reson Imaging; 2022 Aug; 56(2):368-379. PubMed ID: 34953171
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
8. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
Mayo R; Crespo J; Martínez-Arranz I; Banales JM; Arias M; Mincholé I; Aller de la Fuente R; Jimenez-Agüero R; Alonso C; de Luis DA; Vitek L; Stritesky J; Caballería J; Romero-Gómez M; Martín-Duce A; Mugüerza Huguet JM; Busteros-Moraza JI; Idowu MO; Castro A; Martínez-Chantar ML; Ortiz P; Bruha R; Lu SC; Bedossa P; Noureddin M; Sanyal AJ; Mato JM
Hepatol Commun; 2018 Jul; 2(7):807-820. PubMed ID: 30027139
[TBL] [Abstract][Full Text] [Related]
9. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.
Gunn NT; Shiffman ML
Clin Liver Dis; 2018 Feb; 22(1):109-119. PubMed ID: 29128050
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
[TBL] [Abstract][Full Text] [Related]
11. Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis.
Qi S; Xu D; Li Q; Xie N; Xia J; Huo Q; Li P; Chen Q; Huang S
Clin Chim Acta; 2017 Oct; 473():89-95. PubMed ID: 28842175
[TBL] [Abstract][Full Text] [Related]
12. Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis.
Caussy C; Chuang JC; Billin A; Hu T; Wang Y; Subramanian GM; Djedjos CS; Myers RP; Dennis EA; Loomba R
Therap Adv Gastroenterol; 2020; 13():1756284820923904. PubMed ID: 32523627
[TBL] [Abstract][Full Text] [Related]
13. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
[TBL] [Abstract][Full Text] [Related]
14. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
15. [The significance of 8-hydroxy-deoxyguanosine acid in the diagnosis of nonalcoholic steatohepatitis].
Jiang Y; Han T; Zhang ZG; Lu SQ; Mi YQ; Xu L; Qi FX; Zhang Y; Song GD
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):34-38. PubMed ID: 28056321
[No Abstract] [Full Text] [Related]
16. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
[TBL] [Abstract][Full Text] [Related]
19. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
20. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease.
Kim TH; Lee Y; Lee YS; Gim JA; Ko E; Yim SY; Jung YK; Kang S; Kim MY; Kim H; Kim BH; Kim JH; Seo YS; Yim HJ; Yeon JE; Um SH; Byun KS
Sci Rep; 2021 Jul; 11(1):14639. PubMed ID: 34282172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
